Human papillomavirus 16/18 vaccine recombinant bivalent - Xiamen Innovax

Drug Profile

Human papillomavirus 16/18 vaccine recombinant bivalent - Xiamen Innovax

Alternative Names: Cecolin; Human papillomavirus (types 16 and 18) L1 virus-like particle vaccine - Xiamen Innovax; Human papillomavirus 16/18 bivalent vaccine recombinant - Xiamen; Human papillomavirus 16/18 vaccine - Xiamen; Recombinant human papillomavirus bivalent (type 16/18) vaccine - Xiamen Innovax

Latest Information Update: 22 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Xiamen Innovax Biotech
  • Developer Beijing Wantai Bio-pharm; Xiamen Innovax Biotech; Xiamen University
  • Class Cancer vaccines; Papillomavirus vaccines; Synthetic vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Cervical cancer; Human papillomavirus infections

Most Recent Events

  • 08 Jul 2014 Xiamen Innovax Biotech and Beijing Wantai Bio-pharm complete enrolment in a phase III trial in Human papillomavirus infections (Prevention, in volunteers) in China (NCT01735006)
  • 31 Jul 2011 Xiamen University completes a phase I trial in Human papillomavirus infections (prevention) in China (NCT01263327)
  • 17 Dec 2010 Phase-I clinical trials in Cervical cancer prevention in China (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top